| Placebo | Golimumab | Ustekinumab | |
| Treated patients | 58 | 55 | 60 |
| Patients with events | 54 (93.1) | 53 (96.4) | 56 (93.3) |
| Cough | 15 (25.9) | 11 (20.0) | 13 (21.7) |
| Arthralgia | 16 (27.6) | 13 (23.6) | 9 (15.0) |
| Fatigue | 8 (13.8) | 11 (20.0) | 12 (20.0) |
| Headache | 12 (20.7) | 7 (12.7) | 12 (20.0) |
| Upper respiratory tract infection | 13 (22.4) | 6 (10.9) | 10 (16.7) |
| Dyspnoea | 11 (19.0) | 11 (20.0) | 4 (6.7) |
| Diarrhoea | 11 (19.0) | 6 (10.9) | 9 (15.0) |
| Bronchitis | 9 (15.5) | 8 (14.5) | 8 (13.3) |
| Pain in extremity | 11 (19.0) | 3 (5.5) | 8 (13.3) |
| Back pain | 6 (10.3) | 6 (10.9) | 9 (15.0) |
| Nausea | 6 (10.3) | 7 (12.7) | 8 (13.3) |
| Rash | 6 (10.3) | 6 (10.9) | 6 (10.0) |
| Sarcoidosis | 3 (5.2) | 4 (7.3) | 11 (18.3) |
| Sinusitis | 9 (15.5) | 3 (5.5) | 5 (8.3) |
| Oedema peripheral | 5 (8.6) | 8 (14.5) | 4 (6.7) |
| Vomiting | 7 (12.1) | 4 (7.3) | 6 (10.0) |
| Nasopharyngitis | 2 (3.4) | 4 (7.3) | 9 (15.0) |
| Skin lesion | 8 (13.8) | 1 (1.8) | 6 (10.0) |
| Oropharyngeal pain | 4 (6.9) | 2 (3.6) | 7 (11.7) |
Data presented as n or n (%). Percentages were calculated with the number of patients treated in each arm as the denominator. Incidence was based on the number of patients experiencing at least one adverse event, not the number of events.